Deep Dive: Early RSV Spike Collides with Flu Season — Protection Options for Infants, Background, What Changed, Viewpoints, and What to Watch

Background

Respiratory syncytial virus (RSV) is a common seasonal virus that infects nearly every child by age 2. For most older children and adults it causes mild cold-like symptoms, but for infants—especially those under 6 months, premature babies, or those with underlying heart or lung conditions—it can lead to bronchiolitis, pneumonia, and hospitalization. Historically, RSV activity peaks in January or February in much of the United States.

In recent years, patterns shifted after pandemic-era reductions in exposure. During the 2025–2026 season, activity peaked later than usual, prompting many states to extend immunization guidance into April.

What Changed

Clinicians are reporting an early and unusually rapid rise in RSV cases as the 2026–2027 season begins, coinciding with the start of flu season and continued COVID-19 circulation. Some are describing a potential “tripledemic” risk. UCLA Health and others note that current case levels are already high compared with prior years at this calendar point.

At the same time, real-world evidence continues to accumulate on protection options:

• Maternal vaccination with the RSVpreF vaccine (Abrysvo) during pregnancy transfers antibodies to the newborn.

• Long-acting monoclonal antibodies (nirsevimab / Beyfortus or clesrovimab / Enflonsia) given to the infant provide direct protection.

New systematic review and meta-analysis data presented at IDWeek 2026 (drawing on studies from the US, UK, and Argentina covering more than 3,000 mother-infant pairs) found pooled vaccine effectiveness of approximately 75% against RSV hospitalization in the first 6 months of life when the mother was vaccinated at least 14 days before birth. Effectiveness was highest (around 81%) for infants 3 months or younger under the same timing. Timing matters: vaccination less than 14 days before birth showed markedly lower effectiveness in the available data.

Population-level signals from England (where maternal vaccination began in September 2024) showed RSV-related bronchiolitis admissions in babies under 3 months running roughly 63% lower than expected during the 2024–2025 season period, even with modest uptake around 55%.

The American Academy of Pediatrics continues to recommend RSV immunization for all infants under 8 months born during or entering their first RSV season (unless already protected via maternal vaccination) and has expanded high-risk criteria for second-season doses in 2026–2027.

Competing Viewpoints

Public health and pediatric organizations emphasize that both maternal vaccination and infant monoclonal antibodies substantially reduce severe disease and hospitalizations, with the choice often depending on timing of pregnancy, local availability, and individual risk. They stress that protection does not eliminate infection entirely but lowers the chance of serious outcomes.

Some clinicians and parents note residual uncertainties around optimal timing windows, duration of protection into the second season for certain high-risk children, and the practical challenges of ensuring timely administration before peak circulation. Supply, cost-sharing, and access differences across insurance and clinic settings continue to create uneven uptake. A minority of voices continue to question the overall risk-benefit framing or prefer exclusive reliance on natural exposure, though severe infant outcomes remain the dominant clinical concern in published surveillance.

What to Watch Next

• Whether the early RSV rise continues and how it interacts with flu and COVID activity through the winter peak.

• Updated CDC and state surveillance reports on positivity rates and hospitalizations.

• Additional real-world effectiveness data, particularly for the second RSV season and for infants born later in the fall.

• Uptake rates for maternal vaccination (ideally 28–36 weeks, at least 14 days before delivery) and infant monoclonal antibodies.

• Any adjustments to seasonal guidance if activity remains elevated later than historical norms.

Parents of infants, especially those with newborns or babies under 8 months, should discuss RSV protection options with their clinician promptly—before peak season intensifies. Household hand hygiene, limiting exposure for very young infants, and monitoring for signs of breathing difficulty remain practical steps alongside immunization.

This is general information compiled from public reports and is not medical advice. Check with your pediatrician or obstetrician for recommendations specific to your family.